The U.S. Food and Drug Administration (FDA) has stated that 'black box' warnings on menopausal hormone treatments have discouraged many women from using those therapies.
high
general
Regulatory labeling (so-called 'black box' warnings) can influence patient and clinician decisions about medication use.